RayKnowChina Research Map
Shortlist0

RecruitingHepatocellular carcinomaPhase 2

Registered title, quoted from ClinicalTrials.gov

TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk

An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. Led by First Affiliated Hospital of Sun Yat-sen University; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)First Affiliated Hospital of Sun Yat-sen University中山大学附属第一医院GuangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07487662, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 8

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (8 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. 1) Age: 18-75 years old; 2) Patients with hepatocellular carcinoma (HCC) classified as CNLC stage Ib-IIIa (excluding patients with Vp3 and Vp4), and deemed resectable by multidisciplinary team (MDT) discussion;

    Inclusion criterion 1

  3. 1) Prior history of HCC treatment; 2) Tumor rupture and bleeding, or suspected peritoneal metastasis;

    Exclusion criterion 1

    Untreated active hepatitis B subjects (HBsAg positive and HBV-DNA exceeding 5000 copies/mL (1000 IU/mL) or higher than the lower limit of detection, whichever is higher); for subjects with hepatitis B, anti-hepatitis B virus treatment is required during the study treatment; active hepatitis C subjects (HCV antibody positive and HCV-RNA level higher than the lower limit of detection);

    Exclusion criterion 9

  4. ECOG PS score of 0-1;

    Inclusion criterion 4

  5. Hemoglobin concentration ≥ 90 g/L;

    Inclusion criterion 8

    Neutrophil count ≥ 1.5 × 10⁹/L;

    Inclusion criterion 9

    Platelet count ≥ 75 × 10⁹/L;

    Inclusion criterion 10

    Total bilirubin ≤ 1.5 × ULN (Upper Limit of Normal);

    Inclusion criterion 11

    AST and ALT < 5 × ULN; ALP < 4 × ULN;

    Inclusion criterion 12

    Creatinine ≤ 1.5 × ULN;

    Inclusion criterion 13

    INR ≤ 1.5 × ULN; APTT ≤ 1.5 × ULN;

    Inclusion criterion 14

  6. At least one measurable target lesion according to the RECIST 1.1 criteria;

    Inclusion criterion 3

  7. Prior positive HIV test or acquired immunodeficiency syndrome (AIDS);

    Exclusion criterion 12

  8. Women of childbearing age must be excluded from pregnancy;

    Inclusion criterion 16

    Pregnant or lactating women, or subjects planning to have children during the trial period;

    Exclusion criterion 22

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07487662, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • 1) Age: 18-75 years old; 2) Patients with hepatocellular carcinoma (HCC) classified as CNLC stage Ib-IIIa (excluding patients with Vp3 and Vp4), and deemed resectable by multidisciplinary team (MDT) discussion;
  • No prior tumor-related treatment received;
  • At least one measurable target lesion according to the RECIST 1.1 criteria;
  • ECOG PS score of 0-1;
  • Liver function classification: Child-Pugh Class A;
  • Estimated survival time ≥ 12 weeks;
  • Hematological, liver, and renal functions meet the following criteria:
  • Hemoglobin concentration ≥ 90 g/L;
  • Neutrophil count ≥ 1.5 × 10⁹/L;
  • Platelet count ≥ 75 × 10⁹/L;
  • Total bilirubin ≤ 1.5 × ULN (Upper Limit of Normal);
  • AST and ALT < 5 × ULN; ALP < 4 × ULN;
  • Creatinine ≤ 1.5 × ULN;
  • INR ≤ 1.5 × ULN; APTT ≤ 1.5 × ULN;
  • Serum albumin concentration ≥ 30 g/L;
  • Women of childbearing age must be excluded from pregnancy;
  • For patients with other concurrent malignant tumors, MDT discussion must confirm that the history and treatment history of other tumors will not interfere with the efficacy and safety evaluation of this study protocol;
  • Ability to understand and sign the informed consent form.

Exclusion Criteria:

  • 1) Prior history of HCC treatment; 2) Tumor rupture and bleeding, or suspected peritoneal metastasis;
  • History of other complex surgeries within 6 weeks;
  • Prior history of organ transplantation;
  • Currently receiving treatment in other clinical trials;
  • Prior history of autoimmune diseases, inflammatory disorders (such as inflammatory bowel disease, etc.), diverticulitis, systemic lupus erythematosus, sarcoidosis syndrome, Wegener's syndrome (granulomatosis with polyangiitis, rheumatoid arthritis, etc.), except for the following cases: vitiligo or alopecia areata, hypothyroidism with stable condition after drug replacement therapy, chronic skin diseases that do not require systemic treatment, and celiac disease controllable by diet alone;
  • Prior history of allergy to anti-PD1 drugs, TKI or anti-CTLA4 drugs, or allergy to chemical molecules similar to the above drugs, or prior severe allergic reaction to other monoclonal antibodies;
  • Uncontrollable intermittent recurrent diseases, including but not limited to: persistent infections (including tuberculosis), hypertension uncontrollable by drugs (> 140/90 mmHg), interstitial lung disease, severe chronic gastrointestinal diseases complicated with diarrhea, mental illness or social disorders that cannot comply with clinical research requirements, factors with high risk of side effects, and inability to sign the informed consent form;
  • Patients with prior hepatic encephalopathy, refractory ascites, or esophagogastric varices with high bleeding risk; patients with upper gastrointestinal bleeding within 1 year before the first administration;
  • Untreated active hepatitis B subjects (HBsAg positive and HBV-DNA exceeding 5000 copies/mL (1000 IU/mL) or higher than the lower limit of detection, whichever is higher); for subjects with hepatitis B, anti-hepatitis B virus treatment is required during the study treatment; active hepatitis C subjects (HCV antibody positive and HCV-RNA level higher than the lower limit of detection);
  • Patients with primary brain tumors (except meningiomas or other benign brain tumors), or any brain metastases, leptomeningeal carcinomatosis, epilepsy uncontrollable by conventional drugs, or new-onset stroke within 1 year;
  • Primary immunodeficiency disease;
  • Prior positive HIV test or acquired immunodeficiency syndrome (AIDS);
  • Use of immunosuppressive drugs within 14 days before the start of study treatment. The following situations are exempt:
  • Intranasal, inhaled, topically used steroids or local steroid injections;
  • Systemic application of corticosteroids not exceeding the physiological dose (e.g., 10 mg/day prednisone or its equivalent);
  • Steroid application for the treatment of allergic reactions;
  • Vaccination with live-attenuated vaccines within 30 days before the start of study treatment. Note: Live-attenuated vaccines should also be avoided during the study treatment and within 30 days after the end of treatment;
  • Receipt of systemic immunostimulant treatment within the prior 4 weeks;
  • Prior history of severe systemic diseases, including: myocardial infarction or unstable angina pectoris, hypertensive crisis or hypertensive encephalopathy, congestive heart failure of NYHA Class II or above, unstable symptomatic arrhythmia requiring drug intervention, severe vascular disease or symptomatic peripheral vascular disease, occurring within 12 months before the start of study treatment;
  • History of coagulative, hemorrhagic or thrombotic diseases within 12 months before the start of study treatment;
  • Severe, irreversible trauma, ulcers or fractures;
  • Pregnant or lactating women, or subjects planning to have children during the trial period;
  • Dependent on parenteral nutrition to maintain life;
  • Other acute or chronic diseases, mental and psychological diseases, etc., which are not suitable for participating in this study, as judged by the researcher.

Quoted from ClinicalTrials.gov, NCT07487662, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07487662, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07487662